Wellington Management Group LLP Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

Wellington Management Group LLP decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 70.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,425,492 shares of the biopharmaceutical company’s stock after selling 3,404,149 shares during the quarter. Wellington Management Group LLP’s holdings in Xenon Pharmaceuticals were worth $86,043,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth $454,057,000. Siren L.L.C. raised its holdings in Xenon Pharmaceuticals by 62.2% in the 1st quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company’s stock valued at $76,674,000 after buying an additional 505,803 shares during the period. Bank of New York Mellon Corp lifted its position in Xenon Pharmaceuticals by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company’s stock valued at $23,035,000 after buying an additional 8,980 shares during the last quarter. Nicholas Investment Partners LP lifted its position in Xenon Pharmaceuticals by 104.0% in the fourth quarter. Nicholas Investment Partners LP now owns 242,989 shares of the biopharmaceutical company’s stock valued at $10,891,000 after buying an additional 123,891 shares during the last quarter. Finally, Castleark Management LLC purchased a new position in Xenon Pharmaceuticals during the first quarter worth about $3,754,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analysts Set New Price Targets

XENE has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Needham & Company LLC decreased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Finally, Royal Bank Of Canada dropped their target price on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $77.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher John Kenney sold 7,068 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the transaction, the insider directly owned 2 shares of the company’s stock, valued at $120.50. This represents a 99.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 19,580 shares of company stock worth $1,199,935. 2.91% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $60.00 on Wednesday. The business has a 50-day moving average of $63.40 and a 200 day moving average of $56.73. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of -12.66 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the business earned ($1.07) EPS. Equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.